Selected research
Industry Research
Dopamine Agonists Industry Research Report 2026
Market perspective
The global Dopamine Agonists market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Dopamine Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Dopamine Agonists is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Dopamine Agonists is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Dopamine Agonists include ACADIA Pharmaceuticals Inc, Impax Laboratories, Kissei Pharmaceutical Co, UCB, AbbVie, Boehringer Ingelheim, Otsuka Pharmaceutical Co, GSK and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Dopamine Agonists market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Dopamine Agonists Market by Company
ACADIA Pharmaceuticals Inc
Impax Laboratories
Kissei Pharmaceutical Co
UCB
AbbVie
Boehringer Ingelheim
Otsuka Pharmaceutical Co
GSK
Pfizer
Roche
Merck
Teva Pharmaceutical Industries Ltd
Dopamine Agonists Segment by Type
Ergotamine
Non-ergotamine
Dopamine Agonists Segment by Application
Parkinson's
Restless Legs Syndrome
Dopamine Agonists Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dopamine Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dopamine Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dopamine Agonists.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Dopamine Agonists manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Dopamine Agonists by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Dopamine Agonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ergotamine
- Non-ergotamine
Applications
- Parkinson's
- Restless Legs Syndrome
Companies covered
- ACADIA Pharmaceuticals Inc
- Impax Laboratories
- Kissei Pharmaceutical Co
- UCB
- AbbVie
- Boehringer Ingelheim
- Otsuka Pharmaceutical Co
- GSK
- Pfizer
- Roche
- Merck
- Teva Pharmaceutical Industries Ltd
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Dopamine Agonists Market Size (2021-2032)
- 2.2.2 Global Dopamine Agonists Sales (2021-2032)
- 2.2.3 Global Dopamine Agonists Market Average Price (2021-2032)
- 2.3 Dopamine Agonists by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Ergotamine
- 2.3.3 Non-ergotamine
- 2.4 Dopamine Agonists by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Parkinson's
- 2.4.3 Restless Legs Syndrome
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Dopamine Agonists Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Dopamine Agonists Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Dopamine Agonists Revenue of Manufacturers (2021-2026)
- 3.4 Global Dopamine Agonists Average Price by Manufacturers (2021-2026)
- 3.5 Global Dopamine Agonists Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Dopamine Agonists, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Dopamine Agonists, Product Type & Application
- 3.8 Global Manufacturers of Dopamine Agonists, Established Date
- 3.9 Global Dopamine Agonists Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 ACADIA Pharmaceuticals Inc
- 4.1.1 ACADIA Pharmaceuticals Inc Company Information
- 4.1.2 ACADIA Pharmaceuticals Inc Business Overview
- 4.1.3 ACADIA Pharmaceuticals Inc Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 ACADIA Pharmaceuticals Inc Dopamine Agonists Product Portfolio
- 4.1.5 ACADIA Pharmaceuticals Inc Recent Developments
- 4.2 Impax Laboratories
- 4.2.1 Impax Laboratories Company Information
- 4.2.2 Impax Laboratories Business Overview
- 4.2.3 Impax Laboratories Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Impax Laboratories Dopamine Agonists Product Portfolio
- 4.2.5 Impax Laboratories Recent Developments
- 4.3 Kissei Pharmaceutical Co
- 4.3.1 Kissei Pharmaceutical Co Company Information
- 4.3.2 Kissei Pharmaceutical Co Business Overview
- 4.3.3 Kissei Pharmaceutical Co Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Kissei Pharmaceutical Co Dopamine Agonists Product Portfolio
- 4.3.5 Kissei Pharmaceutical Co Recent Developments
- 4.4 UCB
- 4.4.1 UCB Company Information
- 4.4.2 UCB Business Overview
- 4.4.3 UCB Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 UCB Dopamine Agonists Product Portfolio
- 4.4.5 UCB Recent Developments
- 4.5 AbbVie
- 4.5.1 AbbVie Company Information
- 4.5.2 AbbVie Business Overview
- 4.5.3 AbbVie Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 AbbVie Dopamine Agonists Product Portfolio
- 4.5.5 AbbVie Recent Developments
- 4.6 Boehringer Ingelheim
- 4.6.1 Boehringer Ingelheim Company Information
- 4.6.2 Boehringer Ingelheim Business Overview
- 4.6.3 Boehringer Ingelheim Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Boehringer Ingelheim Dopamine Agonists Product Portfolio
- 4.6.5 Boehringer Ingelheim Recent Developments
- 4.7 Otsuka Pharmaceutical Co
- 4.7.1 Otsuka Pharmaceutical Co Company Information
- 4.7.2 Otsuka Pharmaceutical Co Business Overview
- 4.7.3 Otsuka Pharmaceutical Co Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Otsuka Pharmaceutical Co Dopamine Agonists Product Portfolio
- 4.7.5 Otsuka Pharmaceutical Co Recent Developments
- 4.8 GSK
- 4.8.1 GSK Company Information
- 4.8.2 GSK Business Overview
- 4.8.3 GSK Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 GSK Dopamine Agonists Product Portfolio
- 4.8.5 GSK Recent Developments
- 4.9 Pfizer
- 4.9.1 Pfizer Company Information
- 4.9.2 Pfizer Business Overview
- 4.9.3 Pfizer Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Pfizer Dopamine Agonists Product Portfolio
- 4.9.5 Pfizer Recent Developments
- 4.10 Roche
- 4.10.1 Roche Company Information
- 4.10.2 Roche Business Overview
- 4.10.3 Roche Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Roche Dopamine Agonists Product Portfolio
- 4.10.5 Roche Recent Developments
- 4.11 Merck
- 4.11.1 Merck Company Information
- 4.11.2 Merck Business Overview
- 4.11.3 Merck Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Merck Dopamine Agonists Product Portfolio
- 4.11.5 Merck Recent Developments
- 4.12 Teva Pharmaceutical Industries Ltd
- 4.12.1 Teva Pharmaceutical Industries Ltd Company Information
- 4.12.2 Teva Pharmaceutical Industries Ltd Business Overview
- 4.12.3 Teva Pharmaceutical Industries Ltd Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Teva Pharmaceutical Industries Ltd Dopamine Agonists Product Portfolio
- 4.12.5 Teva Pharmaceutical Industries Ltd Recent Developments
5 Global Dopamine Agonists Market Scenario by Region
- 5.1 Global Dopamine Agonists Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Dopamine Agonists Sales by Region: 2021-2032
- 5.2.1 Global Dopamine Agonists Sales by Region: 2021-2026
- 5.2.2 Global Dopamine Agonists Sales by Region: 2027-2032
- 5.3 Global Dopamine Agonists Revenue by Region: 2021-2032
- 5.3.1 Global Dopamine Agonists Revenue by Region: 2021-2026
- 5.3.2 Global Dopamine Agonists Revenue by Region: 2027-2032
- 5.4 North America Dopamine Agonists Market Facts & Figures by Country
- 5.4.1 North America Dopamine Agonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Dopamine Agonists Sales by Country (2021-2032)
- 5.4.3 North America Dopamine Agonists Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Dopamine Agonists Market Facts & Figures by Country
- 5.5.1 Europe Dopamine Agonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Dopamine Agonists Sales by Country (2021-2032)
- 5.5.3 Europe Dopamine Agonists Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Dopamine Agonists Market Facts & Figures by Country
- 5.6.1 Asia Pacific Dopamine Agonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Dopamine Agonists Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Dopamine Agonists Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Dopamine Agonists Market Facts & Figures by Country
- 5.7.1 South America Dopamine Agonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Dopamine Agonists Sales by Country (2021-2032)
- 5.7.3 South America Dopamine Agonists Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Dopamine Agonists Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Dopamine Agonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Dopamine Agonists Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Dopamine Agonists Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Dopamine Agonists Sales by Type (2021-2032)
- 6.1.1 Global Dopamine Agonists Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Dopamine Agonists Sales Market Share by Type (2021-2032)
- 6.2 Global Dopamine Agonists Revenue by Type (2021-2032)
- 6.2.1 Global Dopamine Agonists Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Dopamine Agonists Revenue Market Share by Type (2021-2032)
- 6.3 Global Dopamine Agonists Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Dopamine Agonists Sales by Application (2021-2032)
- 7.1.1 Global Dopamine Agonists Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Dopamine Agonists Sales Market Share by Application (2021-2032)
- 7.2 Global Dopamine Agonists Revenue by Application (2021-2032)
- 7.2.1 Global Dopamine Agonists Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Dopamine Agonists Revenue Market Share by Application (2021-2032)
- 7.3 Global Dopamine Agonists Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Dopamine Agonists Value Chain Analysis
- 8.1.1 Dopamine Agonists Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Dopamine Agonists Production Mode & Process
- 8.2 Dopamine Agonists Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Dopamine Agonists Distributors
- 8.2.3 Dopamine Agonists Customers
9 Global Dopamine Agonists Analyzing Market Dynamics
- 9.1 Dopamine Agonists Industry Trends
- 9.2 Dopamine Agonists Industry Drivers
- 9.3 Dopamine Agonists Industry Opportunities and Challenges
- 9.4 Dopamine Agonists Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst